Hongliang Li
Vice President of Gannan Medical University and Executive Director of its State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases; researcher of cardiovascular and metabolic diseases
Vice President, Gannan Medical University · Executive Director, State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases · Director, Gannan Innovation and Translational Medicine Research Institute
Hongliang Li is Vice President of Gannan Medical University in Ganzhou, China, and Executive Director of its State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, where he also directs the Gannan Innovation and Translational Medicine Research Institute. His research focuses on the mechanisms, prevention and treatment of cardiovascular and metabolic diseases, including cardiac remodeling, and on developing animal models of these diseases.
He is the senior author of a 2026 Circulation study identifying LAPTM4A as a novel booster of mTORC1 signaling in cardiomyocytes, showing that it drives pathological cardiac hypertrophy through a NEDD4L-AKT-mTORC1 axis, and that the FDA-approved compound magnolol suppresses LAPTM4A with cardioprotective effect in mice.
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 2026 | A | Novel mTORC1 Booster LAPTM4A Potentiates Pathological Cardiac Hypertrophy HU2026 Senior author identifying LAPTM4A as a novel mTORC1-activating driver of pathological cardiac hypertrophy via NEDD4L-mediated AKT ubiquitination. |
Co-authors in the Atlas
People with a profile here who share at least one study with Hongliang Li.
- Yufeng Hu 2 shared studies First author of a 2026 Circulation study identifying LAPTM4A as a novel mTORC1 activator driving pathological cardiac hypertrophy